Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-03-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2338 |
| id |
doaj-6d5785e318ec4913882c406369c26ce8 |
|---|---|
| record_format |
Article |
| spelling |
doaj-6d5785e318ec4913882c406369c26ce82021-07-28T13:29:34ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-03-0104868910.21518/2079-701X-2018-4-86-892314Efficacy of liraglutide 3 mig therapy in obesity and associated diseasesK. A. Komshilova0E. A. Troshina1National Medical Research Centre of Endocrinology of the Ministry of Health of RussiaNational Medical Research Centre of Endocrinology of the Ministry of Health of RussiaObesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of the problem, we present a clinical case that shows the efficacy of therapy with liraglutide 3.0 mg daily in a patient with obesity, and its effect on metabolic risk factors.https://www.med-sovet.pro/jour/article/view/2338obesityliraglutide 3.0 mg once dailyanalogue of human glucagon-like peptide-1 |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
K. A. Komshilova E. A. Troshina |
| spellingShingle |
K. A. Komshilova E. A. Troshina Efficacy of liraglutide 3 mig therapy in obesity and associated diseases Медицинский совет obesity liraglutide 3.0 mg once daily analogue of human glucagon-like peptide-1 |
| author_facet |
K. A. Komshilova E. A. Troshina |
| author_sort |
K. A. Komshilova |
| title |
Efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| title_short |
Efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| title_full |
Efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| title_fullStr |
Efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| title_full_unstemmed |
Efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| title_sort |
efficacy of liraglutide 3 mig therapy in obesity and associated diseases |
| publisher |
Remedium Group LLC |
| series |
Медицинский совет |
| issn |
2079-701X 2658-5790 |
| publishDate |
2018-03-01 |
| description |
Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of the problem, we present a clinical case that shows the efficacy of therapy with liraglutide 3.0 mg daily in a patient with obesity, and its effect on metabolic risk factors. |
| topic |
obesity liraglutide 3.0 mg once daily analogue of human glucagon-like peptide-1 |
| url |
https://www.med-sovet.pro/jour/article/view/2338 |
| work_keys_str_mv |
AT kakomshilova efficacyofliraglutide3migtherapyinobesityandassociateddiseases AT eatroshina efficacyofliraglutide3migtherapyinobesityandassociateddiseases |
| _version_ |
1721274040232968192 |